denosumab

denosumab is a human monoclonal antibody used in the treatment of osteoporosis, bone metastases associated with prostate cancer, and giant cell tumor of bone. It is marketed by Amgen and was approved by the United States Food and Drug Administration in 2010. The development of denosumab involved the work of researchers at Amgen and University of California, Los Angeles, including David M. Goldberg and Matthew T. Drake.

● Introduction

Denosumab is used to treat various bone-related diseases, including osteoporosis in postmenopausal women and men with prostate cancer and breast cancer undergoing hormone therapy. The treatment has been shown to reduce the risk of vertebral fractures in patients with osteoporosis, as demonstrated in the FREEDOM trial conducted by Steven R. Cummings and Felicia Cosman. Denosumab has also been used to treat patients with giant cell tumor of bone, a rare type of bone cancer that often affects young adults, as studied by researchers at National Institutes of Health and University of Oxford. The use of denosumab in the treatment of bone metastases has been investigated in clinical trials, including the HALT 100 study, which involved researchers from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

● Mechanism_of_action

Denosumab works by binding to and inhibiting the activity of RANKL, a protein that acts as a ligand for the RANK receptor, which is involved in the formation, function, and survival of osteoclasts. The inhibition of RANKL by denosumab reduces the activity of osteoclasts, leading to a decrease in bone resorption and an increase in bone density, as demonstrated in studies by researchers at University of California, San Francisco and Harvard University. This mechanism of action is similar to that of other osteoporosis treatments, such as bisphosphonates, which are used to treat patients with Paget's disease of bone and osteogenesis imperfecta. The effects of denosumab on bone metabolism have been studied in clinical trials, including the STAND study, which involved researchers from University of Toronto and McGill University.

● Medical_uses

Denosumab is used to treat various medical conditions, including osteoporosis in postmenopausal women and men with prostate cancer and breast cancer undergoing hormone therapy. It is also used to treat patients with giant cell tumor of bone and bone metastases associated with prostate cancer and breast cancer. The use of denosumab in the treatment of multiple myeloma has been investigated in clinical trials, including the 147 study, which involved researchers from University of Chicago and Stanford University. Denosumab has been shown to reduce the risk of skeletal-related events in patients with bone metastases, as demonstrated in the HALT 100 study, which involved researchers from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

● Side_effects

The use of denosumab has been associated with several side effects, including hypocalcemia, hypophosphatemia, and skin infections. Patients treated with denosumab are also at increased risk of developing cellulitis and endocarditis, as reported in studies by researchers at Centers for Disease Control and Prevention and World Health Organization. The risk of osteonecrosis of the jaw is also increased in patients treated with denosumab, particularly those with a history of dental problems or poor oral health, as studied by researchers at University of Michigan and University of California, Los Angeles. The side effects of denosumab have been investigated in clinical trials, including the FREEDOM trial conducted by Steven R. Cummings and Felicia Cosman.

● Pharmacology

Denosumab is administered via subcutaneous injection and has a half-life of approximately 28 days. The pharmacokinetics of denosumab have been studied in clinical trials, including the STAND study, which involved researchers from University of Toronto and McGill University. The bioavailability of denosumab is high, and the drug is not metabolized by the liver or kidneys. The effects of denosumab on bone metabolism have been studied in clinical trials, including the 147 study, which involved researchers from University of Chicago and Stanford University. The use of denosumab in combination with other osteoporosis treatments, such as bisphosphonates, has been investigated in clinical trials, including the HALT 100 study, which involved researchers from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

● History

Denosumab was first approved by the United States Food and Drug Administration in 2010 for the treatment of osteoporosis in postmenopausal women and men with prostate cancer and breast cancer undergoing hormone therapy. The development of denosumab involved the work of researchers at Amgen and University of California, Los Angeles, including David M. Goldberg and Matthew T. Drake. The use of denosumab in the treatment of giant cell tumor of bone and bone metastases associated with prostate cancer and breast cancer was approved by the European Medicines Agency in 2011. The history of denosumab has been marked by several significant events, including the publication of the FREEDOM trial results in the New England Journal of Medicine and the presentation of the STAND study results at the American Society for Bone and Mineral Research annual meeting.

Category:Monoclonal antibodies